sniper said:
ok, so we calculate the exaggeration-factor.
what remains would perhaps be 10 Roche-guys doing contracts with a handful of cyclists and an occasional runner. still sounds dirty.
I can't see why Big Pharma would do such business with athletes. The risk of getting involved in some juicy scandal with celeb atheletes over a few thousand vials of NeoRecormon is just too big compared with the gains. Saleswise, the epo/hgh consumption of the pro athletes is a drop in the ocean compared to the consumption of the patients with e.g. renal failure.
Next, giving some phase I/II drugs to the athletes for testing is a waste of time. You'll never get good quality data usable in research back from cyclists. Too many unknown variables in that equation (using other drugs, missing doses, changes in training/race schedule etc. etc.). And don't expect pro cyclists to come a Swiss lab once a week for blood sampling in an illegitimate protocol.
If Big Pharma wants to get dirty and try out new drugs in shady phase I/II trials, they find a nice hospital with some easygoing doctors in a nice, warm African/Asian/LAtin American country with regulatory bodies willing to look the other way.
Big Pharma are probably dirty in some aspects but pro atheletes make poor guniea pigs and the market is small.
and I do clinical trials and medicine for a living....